NDAORALTABLETPriority Review
Approved
Jan 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
VERQUVO (vericiguat) by Merck & Co. is guanylate cyclase stimulators [moa]. Approved for soluble guanylate cyclase stimulator [epc]. First approved in 2021.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERQUVO (vericiguat) is an oral soluble guanylate cyclase stimulator approved in January 2021 for heart failure patients. It works by activating guanylate cyclase to increase nitric oxide signaling, improving cardiac function and reducing hospitalizations. The drug targets patients with worsening heart failure despite standard therapies.
$34MPart D
Peak6.2 years to LOEProduct is at peak commercial maturity with modest Part D utilization; career roles likely focused on maintaining market position in a competitive heart failure landscape.
Mechanism of Action
Guanylate Cyclase Stimulators
Pharmacologic Class:
Soluble Guanylate Cyclase Stimulator
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression
Started Aug 2026
238 enrolled
Calcific Aortic Valve DiseaseAORTIC VALVE DISEASESAortic Valve Stenosis
An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions
Started Sep 2025
604 enrolled
Chronic Heart Failure With Reduced Ejection FractionWorsening Chronic Heart Failure
The Impact of Vericiguat on Microvascular Function in Patients With Documented Vasospastic Angina Pectoris
Started Feb 2025
57 enrolled
Vasospastic Angina
An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
Started Nov 2024
4,936 enrolled
Chronic Heart FailureChronic Heart Failure With Reduced Ejection Fraction
An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Treated With Vericiguat in Routine Medical Care in Germany
Started Jul 2024
500 enrolled
Chronic Heart Failure With Reduced Ejection Fraction
Worked on VERQUVO at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.